Gilead says clinical trials show coronavirus patients responding to antiviral drug


Gilead Sciences on Wednesday revealed some promising news about remdesivir, an antiviral drug that has been touted as a potential COVID-19 treatment.
The company said its own trial, as well one overseen by the National Institute of Allergy and Infectious Diseases, met its goals, with coronavirus patients reportedly responding well to the drug, reports CNBC. The data from the NIAID is still under wraps, though it's expected to be released at an upcoming briefing.
As for Gilead's trial, which involved 397 patients with severe COVID-19 cases, at least 50 percent of patients treated with a 5-day dosage of remdesivir improved and more than half were discharged from the hospital within two weeks. The overall mortality rate of the study was 7 percent, and relatively few patients developed bad side effects from the drug.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There are caveats, of course. The trial wasn't evaluated against a control group of patients who didn't receive the drug. It's also unclear if the high survival and improvement rates may have been natural recoveries from less severe cases. Still, the news is considered encouraging, albeit far from a "home run," as former Food and Drug Administration Commissioner Scott Gottlieb said after seeing the results. He also reiterated that even if remdesivir is effective, it's a treatment, not a cure.
The NIAID study is considered the most important test, Stat News reports, so the results will be watched closely. Read more at Stat News and CNBC.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Book reviews: 'Girl on Girl: How Pop Culture Turned a Generation of Women Against Themselves' and 'Notes to John'
Feature The aughts' toxic pop culture and Joan Didion's most private pages
-
The FDA plans to embrace AI agencywide
In the Spotlight Rumors are swirling about a bespoke AI chatbot being developed for the FDA by OpenAI
-
Digital consent: Law targets deepfake and revenge porn
Feature The Senate has passed a new bill that will make it a crime to share explicit AI-generated images of minors and adults without consent
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County